Menu Search
Equities

Next Science Ltd

NXSCF:PKC

Next Science Ltd

Actions
  • Price (USD)0.1772
  • Today's Change0.00 / 0.00%
  • Shares traded2.43k
  • 1 Year change-53.18%
  • Beta--
Data delayed at least 15 minutes, as of May 29 2024 14:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.

  • Revenue in AUD (TTM)33.53m
  • Net income in AUD-24.60m
  • Incorporated2017
  • Employees--
  • Location
    Next Science LtdTower BThe Zenith L 19, 821 Pacific HighwayChatswood 2000AustraliaAUS
  • Phone+61 28607-5124
  • Websitehttps://www.nextscience.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.